PSA testing for men — what to know before you have the test

What PSA is

Prostate-specific antigen (PSA) is a protein produced by cells of the prostate gland. Most PSA stays in semen, but small amounts leak into the bloodstream, where it can be measured. Elevated blood PSA can indicate prostate cancer — but also benign prostatic hyperplasia (BPH, the age-related prostate enlargement nearly all older men develop), prostatitis (infection or inflammation), recent ejaculation, recent vigorous exercise, recent urinary tract procedures, or a recent digital rectal examination.

This non-specificity is why PSA isn't a simple cancer test. It's a signal worth investigating further when elevated — not a verdict.

The informed-choice framework

The UK doesn't have a national PSA screening programme like cervical or bowel cancer screening. The NHS Prostate Cancer Risk Management Programme instead supports informed choice for men 50 and over (or 45+ with risk factors) to:

• Understand the benefits and limitations of PSA testing.
• Decide whether to test based on their personal risk profile, values, and preferences.
• Access testing through their GP if they choose to.

The trial evidence is mixed: large European screening trials showed a modest reduction in prostate cancer mortality with PSA screening, but also significant over-diagnosis (treating cancers that wouldn't have caused harm) and over-treatment (treatment side effects affecting men whose cancers were never going to threaten them). Hence the case for shared decision-making rather than blanket screening.

Who should consider testing

NHS informed-choice testing supports men in these groups:

• Men 50 and over. The general informed-choice age.
• Men 45 and over with family history. Father or brother diagnosed with prostate cancer (especially under 65) roughly doubles risk.
• Men 45 and over of Black African or African-Caribbean ethnicity. Around twice the lifetime risk of white men; prostate cancer also tends to present at younger ages and be more aggressive in these groups.
• Men with known BRCA2 mutation. Elevated prostate cancer risk including more aggressive disease.

Outside these groups, the case for testing is weaker but not zero — some men want testing for reassurance or as part of a wider general health check.

Risk factors worth knowing

• Age. The single biggest risk factor. Prostate cancer is rare under 50, common over 70.
• Family history. First-degree relative diagnosed roughly doubles risk; multiple affected relatives or younger-age diagnoses further raise risk.
• Ethnicity. Black African and African-Caribbean men have around twice the lifetime risk of white men. Lower in Asian men.
• Genetic predisposition. BRCA2 (and to a lesser extent BRCA1, Lynch syndrome) elevate risk.
• Lifestyle factors. Obesity and possibly diet associations exist but the evidence is weaker than the demographic factors.

Reference ranges

Standard age-adjusted reference ranges (approximate — lab-specific values may vary):

• Under 50: <2.5 ng/mL
• 50–59: <3.0 ng/mL
• 60–69: <4.0 ng/mL
• 70+: <5.0 ng/mL

Many labs use a flat 4.0 ng/mL cut-off across ages. This is simpler but less age-aware. Either way, the cut-off isn't a binary line — a PSA of 3.8 isn't 'safe' and 4.1 'dangerous'. The trend over time often matters more than a single value.

Free PSA and PSA density

For borderline elevated results, additional measures refine interpretation:

• Free PSA ratio. PSA circulates in 'free' and 'bound' forms. Cancers tend to produce more bound PSA, so a low free PSA ratio (typically <15%) raises cancer concern even when total PSA is borderline.
• PSA density. PSA divided by prostate volume (measured by MRI or ultrasound). Higher density (>0.15 ng/mL/cc) suggests cancer rather than benign enlargement.
• PSA velocity. Rate of rise over time. A faster rise raises concern.

These refinements are usually applied in a urology specialist context rather than in a single-test pharmacy setting, but they explain why a urologist might interpret your number differently than the raw reference range suggests.

What to do before the test

Several things can transiently elevate PSA. To get a reliable result:

• No ejaculation for 48 hours. PSA can rise modestly afterwards.
• No vigorous exercise for 48 hours. Especially cycling — saddle pressure can elevate PSA.
• Avoid testing during or within 6 weeks of urinary tract infection. Infection elevates PSA.
• No recent digital rectal examination (DRE). Wait 1 week.
• No recent urinary catheter or prostate procedure. Wait 6 weeks.
• No fasting required.
• Morning testing is often slightly more accurate.

What an elevated result means

Most elevated PSA results are not cancer. The standard pathway:

1. Repeat after 6–8 weeks. Rules out transient causes (infection, recent activity, lab error).
2. If persistently elevated: referral to urology for further investigation.
3. Multiparametric MRI is now the preferred next investigation in the UK (per NICE NG131). Identifies concerning lesions, reduces unnecessary biopsies.
4. Targeted biopsy only if MRI shows concerning areas.
5. Confirmed cancer: further staging and treatment discussion. Treatment options vary by stage, grade, age, and patient preference — active surveillance, surgery, radiotherapy, hormone therapy, focal therapy.

For low-risk localised cancers, active surveillance (monitoring with regular PSA, MRI, and sometimes repeat biopsy) is often the appropriate first step rather than immediate treatment.

Treatment side effect considerations

Prostate cancer treatment side effects matter to the informed-choice conversation:

• Surgery (radical prostatectomy): meaningful rates of urinary incontinence and erectile dysfunction, even with modern nerve-sparing approaches.
• Radiotherapy: bowel and bladder side effects, secondary cancer risk over years.
• Hormone therapy: hot flushes, weight gain, mood changes, bone density loss, cardiovascular effects.
• Active surveillance: avoids treatment side effects but requires ongoing monitoring and the psychological reality of 'cancer being watched'.

For low-grade, organ-confined cancers, the side-effect cost of treatment can exceed the benefit. Hence the over-treatment concern with universal screening.

Symptoms vs screening

The discussion so far is about screening men without symptoms. Men with prostate-related symptoms (urinary frequency, urgency, weak stream, blood in urine, persistent erectile dysfunction) should see their GP for assessment regardless of screening recommendations. Symptomatic testing is a different conversation.

PSA testing alongside other men's health checks

For men in the informed-choice age range, a wider health check often makes sense:

• Testosterone for symptoms of low T (fatigue, reduced libido, low mood).
• Cardiovascular markers (lipid profile, HbA1c, blood pressure).
• Kidney and liver function.
• Vitamin D, B12, ferritin for fatigue or general wellness checks. See vitamin D and iron / ferritin guides.

For the broader picture see our private blood test guide.

The Leicester clinic context

We process PSA testing through UKAS-accredited labs with 24–48 hour turnaround. Results are reviewed by Mohammed Kolia (Superintendent Pharmacist, GPhC 2073260) with annotated context and clear next-step recommendations. Free summary letter to your GP if follow-up is needed.

For the Leicester demographic, the elevated lifetime risk among Black African and African-Caribbean men is particularly relevant — the informed-choice conversation starts younger (45+) for these groups.

What we cover in a PSA consultation

• Your personal risk profile (age, family history, ethnicity, symptoms).
• The benefits and limitations of PSA testing.
• What test results would mean for you and what pathways follow.
• Preparation instructions before the blood test.
• Post-result discussion and GP letter if needed.

The next step

If you're in the informed-choice age range and want to discuss PSA testing, a 15-minute consultation covers the considerations and — if you choose to proceed — we can take the blood sample same visit. Don't go from 'should I test?' to 'I have cancer' on Google in between — the conversation matters.